A Chinese medicine composition for preventing and treating arteriosclerosis and coronary heart disease

Through the traditional Chinese medicine composition with clear ingredients, including apigenin and other ingredients, the problem of unclear effective ingredients in the existing traditional Chinese medicine formulas has been solved, and the significant therapeutic effect and safety improvement of arteriosclerosis and coronary heart disease has been achieved.

CN118593536BActive Publication Date: 2024-11-29WEIHAI RENSHENG PHARMA GRP CO LTD

Patent Information

Application Number
CN202410777584.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-06-17
Publication Date
2024-11-29
Estimated Expiration
2044-06-17

AI Technical Summary

Technical Problem

The effective ingredients in the existing traditional Chinese medicine formulas are unclear, which leads to a large dosage of the medicine, making it difficult to achieve refined therapeutic effects, especially in the prevention and treatment of arteriosclerosis and coronary heart disease.

Method used

A traditional Chinese medicine composition consisting of clear ingredients is proposed, including apigenin, vitamin B1, eflavin, beta-dehydrated icaridin, jujube saponin, hypericin, methyl salvia ester, tanshinone, betasteine ​​and betasteine ​​and Lycium barbarum polysaccharide is prepared into a variety of dosage forms such as capsules, tablets, etc. through different proportions of combinations, which are used to treat arteriosclerosis and coronary heart disease.

Benefits of technology

The therapeutic effect of clear ingredients and reduced dose has been achieved, which has significantly improved the treatment effect and safety, improved medication compliance, and different proportions have a significant impact on the treatment effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
Patent Text Reader

Abstract

The invention discloses a Chinese medicine composition for preventing and treating arteriosclerosis and coronary heart disease, and relates to the technical field of Chinese medicine. The Chinese medicine composition of the invention comprises the following ingredients: apigenin, vitamin B1, rhubarb, β-anhydroicariin, jujube saponin, hyperoside, salvia miltiorrhiza acid methyl ester, tanshinone, betulinic acid, betaine and wolfberry polysaccharide. The composition is composed of a clear combination of ingredients, achieves a reduced prescription and reduced dosage, and has a significant therapeutic effect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicines, and in particular to a traditional Chinese medicine composition for preventing and treating arteriosclerosis and coronary heart disease. Background Art

[0002] Atherosclerosis is an inflammatory disease of the arteries, which can cause the arterial wall to thicken and harden, lose elasticity, and narrow the lumen. Atherosclerosis is a vascular disease that occurs as people age. It usually occurs in adolescence and worsens and develops in middle-aged and elderly people. Atherosclerosis (AS) is a common type of arteriosclerosis obliterans and the main factor leading to cardiovascular and cerebrovascular diseases such as coronary heart disease. It mainly affects large and medium-sized arteries in the body, such as coronary arteries, cerebral arteries, carotid arteries, femoral arteries, etc.

[0003] AS is a disease in which lipid substances such as cholesterol are deposited in the intima and subintima of the arterial wall of arteries and their branches, accompanied by smooth muscle cell proliferation, forming atherosclerotic plaques, which eventually lead to narrowing of the arterial diameter and thickening and hardening of the arterial wall. At present, there are many theoretical studies on the mechanism of AS, such as hemodynamic theory, thrombogenic theory, vascular smooth muscle cell proliferation theory, lipid infiltration theory, intimal injury response theory and receptor theory. Current research hotspots are mainly centered on theories such as oxidative stress-inflammatory response, endothelial dysfunction and vascular smooth muscle proliferation. In traditional Chinese medicine, AS belongs to the category of "pulse stasis and blood stasis", and coronary heart disease belongs to the category of "chest stasis and heart pain". Its pathogenesis is the deficiency of the root and the excess of the symptoms, which is mostly caused by qi deficiency and blood stasis, with blood stasis as the symptom and qi deficiency as the root. Therefore, Chinese medicines that invigorate qi and activate blood circulation are often used in clinical practice to prevent and treat AS and coronary heart disease.

[0004] Chinese patent CN113304235A discloses a Chinese medicine composition and its preparation method and application, wherein the Chinese medicine composition comprises the following raw materials in parts by weight: 10-35 parts of bupleurum, 5-25 parts of immature bitter orange, 3-20 parts of raw rhubarb, 3-20 parts of scutellaria, 3-20 parts of white peony root, 3-15 parts of dried ginger, 5-20 parts of leech, 3-20 parts of liquorice, 3-20 parts of codonopsis, 3-20 parts of atractylodes, 3-25 parts of pinellia. The Chinese medicine composition of the invention has excellent effects of lowering blood lipids, lowering cholesterol, especially lowering blood triglycerides, and also has good effects of slowing down the formation of atherosclerotic plaques, clearing atherosclerotic plaques, and preventing and treating atherosclerosis.

[0005] Chinese patent CN108096398A discloses a Chinese medicine prescription for treating arteriosclerosis obliterans, which is mainly made of Herba Lysimachiae, Radix Astragali, Pheretima, Radix Paeoniae Rubra, Rhizoma Alismatis, Scorpio, Fructus Liquidambar, Rhizoma Corydalis, Radix Glycyrrhizae, and Flos Lonicerae. After using the prescription, the cure rate of limb pain is 60%, the cure rate of limb coldness is 68.7%, the cure rate of limb numbness is 70%, and the cure rate of intermittent claudication is 68.3%.

[0006] Although most of the current Chinese medicine formulas have good therapeutic effects, due to the large number of active ingredients in each Chinese medicinal material and the large number of types of Chinese medicinal materials involved in Chinese medicine formulas, there are problems such as unclear active ingredients and large dosages.

[0007] In view of this, the present invention provides a Chinese medicine composition with clear ingredients and significant medicinal effects for arteriosclerosis and coronary heart disease. Summary of the invention

[0008] The purpose of the present invention is to provide a Chinese medicine composition for preventing and treating arteriosclerosis and coronary heart disease. Based on the research on Kangxin Capsules, a Chinese medicine composition with refined effective ingredients is proposed. The composition is composed of a clear combination of ingredients, achieves reduction in prescription and dosage, and has a significant therapeutic effect.

[0009] To achieve the above-mentioned object of the invention, the technical solution of the present invention is as follows:

[0010] In one aspect, the present invention provides a traditional Chinese medicine composition comprising the following ingredients: apigenin, vitamin B1, rhamnolide, β-anhydroicariin, jujube saponin, hyperoside, salvia miltiorrhiza acid methyl ester, tanshinone, betulinic acid, betaine and wolfberry polysaccharide.

[0011] Preferably, the Chinese medicine composition comprises the following ingredients in parts by weight: 10-30 parts of apigenin, 0.1-1 part of vitamin B1, 1-5 parts of rhein, 0.1-2 parts of β-anhydroicariin, 5-15 parts of jujube saponin, 10-25 parts of hyperoside, 1-5 parts of methyl salvianolic acid, 0.1-1 part of tanshinone, 0.1-1 part of betulinic acid, 1-10 parts of betaine and 1-10 parts of wolfberry polysaccharides.

[0012] Further preferably, the Chinese medicine composition comprises the following ingredients in parts by weight: 15-25 parts of apigenin, 0.2-0.8 parts of vitamin B1, 2-3 parts of rhamnolide, 0.5-1.5 parts of β-anhydroicariin, 8-12 parts of jujube saponin, 15-20 parts of hyperoside, 2-3 parts of methyl salvianolic acid, 0.2-0.8 parts of tanshinone, 0.2-0.6 parts of betulinic acid, 3-8 parts of betaine and 3-8 parts of wolfberry polysaccharides.

[0013] Most preferably, the Chinese medicine composition comprises the following ingredients in parts by weight: 22 parts of apigenin, 0.4 parts of vitamin B1, 2.5 parts of rhein, 1 part of β-anhydroicariin, 11 parts of jujube saponin, 18 parts of hyperoside, 2.5 parts of methyl salvianolic acid, 0.5 parts of tanshinone, 0.3 parts of betulinic acid, 5 parts of betaine and 5 parts of wolfberry polysaccharides.

[0014] In yet another aspect, the present invention provides a medicine, the effective ingredients of which include the above-mentioned Chinese medicine composition.

[0015] The drug can be prepared into dosage forms such as pills, capsules, granules, oral liquids, powders, tablets, lozenges, etc., and suitable drug carriers in the art can be selected for different dosage forms.

[0016] The pharmaceutical carrier used can be solid, liquid or gas. Examples of solid carriers include lactose, kaolin, sucrose, talc, gelatin, agar, pectin, gum arabic, magnesium stearate and stearic acid. Examples of liquid carriers include syrup, peanut oil, olive oil and water. Examples of gaseous carriers include carbon dioxide and nitrogen.

[0017] When preparing the composition for oral dosage form, any convenient pharmaceutical medium can be used. For example, water, ethanol, oil, alcohol, flavoring agent, preservative, coloring agent, etc. can be used to form oral liquid preparations, such as suspensions, elixirs and solutions; while carriers, such as starch, sugars, microcrystalline cellulose, diluents, granulating agents, emulsifiers, lubricants, binders, disintegrants can be used to form oral solid preparations, such as powders, capsules and tablets. Tablets and capsules are preferred oral dosage units using solid pharmaceutical carriers due to their ease of administration. Tablets can be coated using standard aqueous or non-aqueous techniques.

[0018] Tablets containing the Chinese medicine composition of the present invention can be prepared by tableting or molding, and one or more auxiliary ingredients or adjuvants can be used. The active ingredient can be tableted in a free-flowing form (such as powder or granules) in a suitable machine, and can be mixed with an adhesive, a lubricant, an inert diluent, a surfactant or a dispersant to prepare a tablet. Molded tablets can be molded in a suitable machine, i.e., a powdered compound mixture moistened with an inert liquid diluent. Each tablet preferably contains about 0.05 mg to about 5 g of active ingredient, and each sachet or capsule preferably contains about 0.05 mg to about 5 g of active ingredient. For example, a preparation intended for oral administration to humans may contain about 0.5 mg to about 5 g of active drug, mixed with an appropriate and convenient carrier material, which may account for about 5% to 95% of the total composition. The unit dosage form usually contains about 1 mg to about 2 g of active ingredient, usually 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg or 1000 mg.

[0019] The pharmaceutical composition suitable for parenteral administration of the present invention can be prepared as an aqueous solution or suspension of the active compound. Suitable surfactants such as hydroxypropylcellulose can be included. Dispersions can also be prepared in glycerol, liquid polyethylene glycol and oil mixtures thereof. In addition, preservatives can be added to prevent the harmful growth of microorganisms.

[0020] Medicine of the present invention can be in the form suitable for topical use, for example aerosol, cream, ointment, lotion, powder or the like. In addition, composition can be in the form suitable for transdermal administration device. Can use Chinese medicine composition of the present invention, prepare these prescriptions by conventional processing method. For example, by mixing hydrophilic material and water, and about 5wt% to about 10wt% of compound, prepare cream or ointment with required consistency.

[0021] The medicine of the present invention can be in a form suitable for rectal administration, wherein the carrier is a solid. Preferably, the mixture is made into a unit dose suppository. Suitable carriers include cocoa butter and other materials commonly used in the art. Suppositories can be prepared by first forming a composition containing a softened or melted carrier, followed by cooling and shaping in a mold.

[0022] In addition to the above-mentioned carrier components, the above-mentioned pharmaceutical preparations may include (if applicable) one or more additional carrier components, such as diluents, buffers, flavoring agents, binders, surfactants, thickeners, lubricants, preservatives (including antioxidants), etc. In addition, other excipients, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, etc., colorants and flavoring agents, etc., may be added.

[0023] Preferably, the pharmaceutical preparation is an oral pharmaceutical preparation.

[0024] More preferably, the oral pharmaceutical preparation is any one of a decoction, a pill, a tablet, a capsule, a powder, a granule, and an oral liquid.

[0025] More preferably, the oral pharmaceutical preparation is any one of capsules, powders and granules.

[0026] Finally, the present invention provides the use of the above-mentioned Chinese medicine composition in the preparation of drugs for preventing and / or treating arteriosclerosis and coronary heart disease.

[0027] Preferably, the arteriosclerosis includes arteriolosclerosis, medial arteriosclerosis and atherosclerosis.

[0028] The beneficial effects of the present invention are:

[0029] The Chinese medicine composition of the invention is composed of clear ingredients and has significant therapeutic effects on arteriosclerosis and coronary heart disease. At the same time, the prescription and dosage are reduced, thereby improving safety and medication compliance. DETAILED DESCRIPTION

[0030] In order to make the technical means, creative features, purpose and efficacy of the present invention easy to understand, the present invention is further explained in conjunction with specific embodiments below, but the following embodiments are only preferred embodiments of the present invention, not all. Based on the embodiments in the implementation mode, other embodiments obtained by those skilled in the art without creative work all belong to the protection scope of the present invention. In the following embodiments, unless otherwise specified, the operating methods used are conventional operating methods, the equipment used are conventional equipment, and the equipment materials used in each embodiment are the same.

[0031] Apigenin CAS No: 520-36-5;

[0032] Vitamin B1CAS No: 59-43-8;

[0033] Rhein CAS No: 518-82-1;

[0034] β-Anhydroicariin CAS No: 38226-86-7;

[0035] Jujube saponin CAS No: 55466-04-1;

[0036] Hyperoside CAS: 482-36-0;

[0037] Salvianic acid methyl ester CAS No: 18867-19-9;

[0038] Tanshinone CAS No: 568-73-0;

[0039] Betulinic acid CAS No: 472-15-1;

[0040] Betaine CAS No: 107-43-7;

[0041] Lycium barbarum polysaccharide CAS No: 107-43-7.

[0042] The above materials are all commercially available with a purity of 98% or above, and do not constitute any special limitation to the present invention.

[0043] The following examples and comparative examples are all prepared according to the following method: the raw materials in the formula amount are fully mixed to obtain.

[0044] Example 1

[0045] Formula: 22 parts of apigenin, 0.4 parts of vitamin B1, 2.5 parts of rhamnolide, 1 part of β-anhydroicariin, 11 parts of jujube saponin, 18 parts of hyperoside, 2.5 parts of methyl salvianolic acid, 0.5 parts of tanshinone, 0.3 parts of betulinic acid, 5 parts of betaine and 5 parts of wolfberry polysaccharide.

[0046] Example 2

[0047] Formula: 15 parts of apigenin, 0.8 parts of vitamin B1, 2 parts of rhamnolide, 1.5 parts of β-anhydroicariin, 8 parts of jujube saponin, 20 parts of hyperoside, 2 parts of methyl salvianolic acid, 0.8 parts of tanshinone, 0.2 parts of betulinic acid, 8 parts of betaine and 3 parts of wolfberry polysaccharide.

[0048] Example 3

[0049] Formula: 25 parts of apigenin, 0.2 parts of vitamin B1, 3 parts of rhein, 0.5 parts of β-anhydroicariin, 12 parts of jujube saponin, 15 parts of hyperoside, 3 parts of methyl salvianolic acid, 0.2 parts of tanshinone, 0.6 parts of betulinic acid, 3 parts of betaine and 8 parts of wolfberry polysaccharide.

[0050] Example 4

[0051] Formula: 10 parts of apigenin, 1 part of vitamin B1, 1 part of rhein, 2 parts of β-anhydroicariin, 5 parts of jujube saponin, 25 parts of hyperoside, 1 part of methyl salvianolic acid, 1 part of tanshinone, 0.1 part of betulinic acid, 10 parts of betaine and 1 part of wolfberry polysaccharide.

[0052] Example 5

[0053] Formula: 30 parts of apigenin, 0.1 parts of vitamin B1, 5 parts of rhein, 0.1 parts of β-anhydroicariin, 15 parts of jujube saponin, 10 parts of hyperoside, 5 parts of methyl salvianolic acid, 0.1 parts of tanshinone, 1 part of betulinic acid, 1 part of betaine and 10 parts of wolfberry polysaccharides.

[0054] Comparative Example 1

[0055] Formula: 22 parts of apigenin, 0.4 parts of vitamin B1, 2.5 parts of rhein, 1 part of β-anhydroicariin, 29 parts of hyperoside, 2.5 parts of methyl salvianolic acid, 0.8 parts of tanshinone, 5 parts of betaine and 5 parts of wolfberry polysaccharide.

[0056] Comparative Example 2

[0057] Formula: 22 parts of astragalus polysaccharide, 0.4 parts of vitamin B1, 2.5 parts of isorhamnetin, 1 part of β-anhydroicariin, 11 parts of polygonatum saponin, 18 parts of hyperoside, 2.5 parts of methyl salvianolic acid, 0.5 parts of tanshinone, 0.3 parts of betulinic acid, 5 parts of betaine and 5 parts of wolfberry polysaccharide.

[0058] Comparative Example 3

[0059] Formula: 5 parts of apigenin, 0.1 parts of vitamin B1, 5 parts of rhein, 0.1 parts of β-anhydroicariin, 20 parts of jujube saponin, 30 parts of hyperoside, 10 parts of methyl salvianolic acid, 0.1 parts of tanshinone, 1 part of betulinic acid, 1 part of betaine and 0.5 parts of wolfberry polysaccharide.

[0060] Comparative Example 4

[0061] Recipe: 5 parts of wolfberry, 6 parts of Polygonum multiflorum, 5 parts of Ligustrum lucidum, 6 parts of Angelica sinensis, 11 parts of Cuscuta australis, 5 parts of Epimedium, 11 parts of Polygonatum sibiricum, 5 parts of Salvia miltiorrhiza, 8 parts of Crataegus pinnatifida, 5 parts of Semen Ziziphi spinosae, 11 parts of Chrysanthemum and 5 parts of Lycium bark.

[0062] Results

[0063] Detection method:

[0064] 1. Male Wistar rats, weighing 200 ± 20g, half male and half female, were fed with common feed adaptability for one week, and the rats were randomly divided into 11 groups, 10 in each group, 1 of which was a blank group, 1 was a model group, and the remaining 9 were experimental groups. Intragastric administration, the experimental group was administered with the composition of Examples 1-5 and Comparative Examples 1-4 respectively, and the drug and pure water were fully mixed to form a suspension, and intragastric administration was performed once a day, with a dosage of 0.1 mg / kg and an intragastric volume of 3.6 mL / kg. The blank group and the model group were intragastrically administered with an equal volume of normal saline, and intragastric administration was performed once a day for 4 consecutive weeks. One hour after the last administration, tail vein blood was taken to measure total cholesterol content (TC), serum triglyceride content (TG), serum low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol content (HDL-C).

[0065] 2. Male Wistar rats, weighing 200±20 g, half male and half female, were adaptively fed for one week, and the rats were randomly divided into 10 groups, 10 rats in each group, of which 1 group was a blank group and the remaining 9 groups were experimental groups. The experimental groups were administered with the compositions of Examples 1-5 and Comparative Examples 1-4 respectively, and the drugs and purified water were fully mixed to form a suspension, which was administered with oral administration once a day, with a dosage of 0.1 mg / kg and an oral administration volume of 3.6 mL / kg. The blank group was administered with the same volume of normal saline, once a day, for 1 week. One hour after the last administration, the rats were placed in an inverted beaker with 4 mL of chloroform cotton balls (1 mL of chloroform was added for each replacement of one rat), and the rats were immediately removed and the chest cavity was opened after breathing stopped to observe whether ventricular fibrillation occurred, and the number of animals with ventricular fibrillation was recorded.

[0066] Test results:

[0067]

[0068] Note: Compared with the model group, * is P < 0.05, ** is P < 0.01

[0069] The results showed that compared with the blank group, the total cholesterol content (TC), serum triglyceride content (TG), and serum low-density lipoprotein cholesterol (LDL-C) content of the model group rats with a high-fat diet were significantly increased, and the high-density lipoprotein cholesterol content (HDL-C) content was significantly decreased. The rats treated with the composition of Examples 1-5 of the present invention had significantly decreased TC, TG, and LDL-C contents, significantly increased HDL-C content, and more stable lipid metabolism, indicating that the composition can achieve the treatment of atherosclerosis by balancing the lipid metabolism of rats. Among them, the therapeutic effect of the formula of Example 1 is the best. The results of Comparative Examples 1-3 show that different ingredient combinations and different ratios have a significant effect on the effect. Comparative Example 4 is a combination of medicinal materials, and the results show that most indicators did not show significant therapeutic effects at the test dose.

[0070]

[0071] The results showed that compared with the blank group, the compositions of Examples 1-5 could reduce the number of rats with chloroform-induced arrhythmia, and the results of Comparative Examples 1-3 showed that different combinations of ingredients and different ratios may weaken the antagonistic effect. Comparative Example 4 was a combination of medicinal materials, which did not show an antagonistic effect at the test dose.

[0072] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A Chinese medicine composition, characterized in that: The invention comprises the following ingredients in parts by weight: 10-30 parts of apigenin, 0.1-1 parts of vitamin B1, 1-5 parts of rhein, 0.1-2 parts of β-anhydroicariin, 5-15 parts of jujube saponin, 10-25 parts of hyperoside, 1-5 parts of methyl salvianolic acid, 0.1-1 parts of tanshinone, 0.1-1 parts of betulinic acid, 1-10 parts of betaine and 1-10 parts of wolfberry polysaccharide.

2. The Chinese medicine composition according to claim 1, characterized in that: According to weight parts, it includes the following ingredients: 15-25 parts of apigenin, 0.2-0.8 parts of vitamin B1, 2-3 parts of rhamnolide, 0.5-1.5 parts of β-anhydroicariin, 8-12 parts of jujube saponin, 15-20 parts of hyperoside, 2-3 parts of methyl salvianolic acid, 0.2-0.8 parts of tanshinone, 0.2-0.6 parts of betulinic acid, 3-8 parts of betaine and 3-8 parts of wolfberry polysaccharide.

3. The Chinese medicine composition according to claim 2, characterized in that: In parts by weight, the invention comprises the following ingredients: 22 parts of apigenin, 0.4 parts of vitamin B1, 2.5 parts of rhamnolide, 1 part of β-anhydroicariin, 11 parts of jujube saponin, 18 parts of hyperoside, 2.5 parts of methyl salvianolic acid, 0.5 parts of tanshinone, 0.3 parts of betulinic acid, 5 parts of betaine and 5 parts of wolfberry polysaccharide.

4. A drug, characterized in that The effective ingredients include the Chinese medicine composition according to any one of claims 1 to 3.

5. The drug according to claim 4, characterized in that The dosage form of the drug is an oral pharmaceutical preparation.

6. The drug according to claim 5, characterized in that The oral pharmaceutical preparation is any one of a decoction, a pill, a tablet, a capsule, a powder, a granule, and an oral liquid.

7. The drug according to claim 6, characterized in that The oral pharmaceutical preparation is any one of capsules, powders and granules.

8. Use of the Chinese medicine composition according to any one of claims 1 to 3 in the preparation of drugs for preventing and / or treating arteriosclerosis and coronary heart disease.

9. The use according to claim 8, characterized in that: The arteriosclerosis includes arteriosclerosis of small arteries, medial arteriosclerosis, and atherosclerosis.

Citation Information

Patent Citations

  • Traditional Chinese medicine prescription for treating arteriosclerosis obliterans

    CN108096398A

  • Traditional Chinese medicine composition as well as preparation method and application thereof

    CN113304235A

  • Lipid-lowering flavonoid

    CN106380459A

  • Plant oil composition for resisting atherosclerosis

    CN107198248A

  • Pharmaceutical composition containing icaritin, icaritin derivatives, salts of icaritin and icaritin derivatives and solubilizer

    CN107982249A

Cited By

  • Application of qi-blood foundation strengthening oral liquid in preparation of medicine for improving hyperlipidemia

    CN121550346A